| Biomarker ID | 235 |
| PMID | 17460773 |
| Year | 2007 |
| Biomarker | ARL6IP+MYH11 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Smooth muscle contraction,Sema4D in semaphorin signaling,Muscle cont,Semaphorin interactions,Viral myocarditisraction |
| Experiment | Primary Vs Metastatic Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Two prostate cancer data sets including the Pittsburgh and the LaTulippe et al. (Memorial Sloan- Kettering Cancer Center, MSKCC) data sets were retrieved to distinguish metastatic prostate cancer (MET) and PCA |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | NA |
| Clinical | No |
| Remarks | Results on Stanford Data Set (Validation Set). Classifier Used: IF (ARL6IP > MYH11) THEN MET |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | ARL6IP1, MYH11 |